Esperion Therapeutics, Inc. Share Price
ESPREsperion Therapeutics, Inc. Stock Performance
Open $2.29 | Prev. Close $2.33 | Circuit Range N/A |
Day Range $2.26 - $2.32 | Year Range $0.69 - $4.17 | Volume 90,344 |
Average Traded $2.30 |
Esperion Therapeutics, Inc. Share Price Chart
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
07-Apr-26 | $2.50 | $2.31 | -9.41% |
06-Apr-26 | $2.65 | $2.55 | -2.49% |
02-Apr-26 | $2.54 | $2.62 | +0.19% |
01-Apr-26 | $2.78 | $2.61 | -4.74% |
31-Mar-26 | $2.73 | $2.74 | +4.18% |
30-Mar-26 | $2.74 | $2.63 | -4.19% |
27-Mar-26 | $2.81 | $2.75 | -4.02% |
FAQs on Esperion Therapeutics, Inc. Share Price
Can I buy Esperion Therapeutics, Inc. shares in India?
What is the share price of Esperion Therapeutics, Inc.?
What is the 5 year returns of Esperion Therapeutics, Inc.?
What are the high & low stock price of Esperion Therapeutics, Inc. today?
What is the 52-week high and low of Esperion Therapeutics, Inc. stock?